Gray Cameron
Known title: DirectorCIK: 0001590583
Associated companies
Transaction History
| CUE | ▼ Sell | Other | 61,111 | $165K | 6/14/2022 | View on chart |
| CUE | ▼ Sell | Tax Withholding | 51,562 | $165K | 6/14/2022 | View on chart |
| CUE | ▼ Sell | Other | 61,111 | $165K | 6/14/2022 | View on chart |
| CUE | ▼ Sell | Tax Withholding | 51,562 | $165K | 6/14/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.